Researchers studied the drug Tocilizumab in a randomized controlled trial to help treat hypoxia and inflammation in hospitalized adult COVID-19 patients. A total of 2,022 cases received a single dose of tocilizumab based on their bodyweight over 60 minutes, and 2,094 controls received usual care. Tocilizumab use was correlated with reduced mortality and greater probability of discharge from hospital in 28 days compared with usual care alone. Additionally, the drug was correlated with reduced risk of requiring invasive mechanical ventilation or death in those not already on ventilation compared to usual care alone. These results show that for patients with severe COVID-19, treatment with tocilizumab can increase survival, discharge, and reduce ventilation.